A RECEN T analysis of US Food &
Drug Administration (FDA) novel
anticoagulant (NOAC) adverse
events suggested that Bristol-Myer
Squibb & Pfizer’s Eliquis (apixaban)
was safer than its rivals, Johnson
& Johnson and Bayer’s Xarelto
(rivaroxaban) and Boehringer
Ingelheim’s Pradaxa (dabigatran).
The rivals argue it’s too early to
compare adverse-event reports on
the newest drug in the class with
those that have been on the market
years longer and have been used by
millions more patients.
Both Xarelto and Pradaxa have
multiple indications and extensive
use while Janssen (subsidiary
of J&J) has told FiercePharma,
“Apixaban was approved recently
for one clinical use.
“In just over one year, it has been
prescribed to far fewer patients and
may not yet have an established
pattern in reported adverse
events.”The above article was sent to subscribers in Pharmacy Daily's issue from 05 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Mar 14
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.